1. Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
- Author
-
Hernandez-Mijares A, Bañuls C, Rovira-Llopis S, Diaz-Morales N, Escribano-Lopez I, de Pablo C, Alvarez A, Veses S, Rocha M, and Victor VM
- Subjects
- Aged, Biomarkers blood, Cell Adhesion Molecules blood, Cells, Cultured, Coculture Techniques, Endothelial Cells metabolism, Female, Humans, Hypercholesterolemia blood, Hypercholesterolemia diagnosis, Leukocytes metabolism, Male, Membrane Potential, Mitochondrial drug effects, Middle Aged, Mitochondria metabolism, Oxidative Stress drug effects, Spain, Time Factors, Treatment Outcome, Anticholesteremic Agents therapeutic use, Cell Adhesion drug effects, Cholesterol blood, Endothelial Cells drug effects, Ezetimibe therapeutic use, Ezetimibe, Simvastatin Drug Combination therapeutic use, Hypercholesterolemia drug therapy, Leukocytes drug effects, Mitochondria drug effects, Simvastatin therapeutic use
- Abstract
Background: Cholesterol-lowering therapy has been related with several beneficial effects; however, its influence on oxidative stress and endothelial function is not fully elucidated., Aims: To investigate the effect of simvastatin and ezetimibe on mitochondrial function and leukocyte-endothelium interactions in polymorphonuclear cells of hyperlipidemic patients., Methods: Thirty-nine hyperlipidemic patients were randomly assigned to one of two groups: one received simvastatin (40 mg/day) and the other received ezetimibe (10 mg/day) for 4 weeks, after which both groups were administered combined therapy for an additional 4-week period. Lipid profile, mitochondrial parameters (oxygen consumption, reactive oxygen species (ROS) and membrane potential), glutathione levels, superoxide dismutase activity, catalase activity and leukocyte/endothelial cell interactions and adhesion molecules -VCAM-1, ICAM-1, E-selectin, were evaluated., Results: An improvement in lipid profile was observed after administration of simvastatin or ezetimibe alone (LDLc: -40.2 vs -19.6%, respectively), though this effect was stronger with the former (p < 0.001), and a further reduction was registered when the two were combined (LDLc: -50.7% vs -56.8%, respectively). In addition to this, simvastatin, ezetimibe and simvastatin + ezetimibe significantly increased oxygen consumption, membrane potential and glutathione content, and decreased levels of ROS, thereby improving mitochondrial function. Furthermore, simvastatin + ezetimibe increased catalase activity. In addition, simvastatin and simvastatin/ezetimibe improved leukocyte/endothelium interactions by decreasing leukocyte rolling and adhesion and increasing leukocyte rolling velocity. Finally, simvastatin, ezetimibe and simvastatin + ezetimibe reduced levels of the adhesion molecule ICAM-1, and ezetimibe + simvastatin significantly decreased levels of E-selectin., Conclusion: Co-administration of simvastatin and ezetimibe has an additive cholesterol-lowering effect and beneficial consequences for mitochondrial function and leukocyte/endothelium interactions in leukocytes of hypercholesterolemic patients., (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF